Vanda的传统药物可以显着减少服用GLP-1的人的恶心

2025-11-18 22:34

A phase 2 trial of Vanda Pharmaceuticals' (VNDA) tradipitant found that the oral therapy tradipitant significantly reduced risk of nausea and vomiting in those taking Novo Nordisk's (NVO) GLP-1 weight loss drug Wegovy (semaglutide).
The study enrolled 116 individuals who received either tradipitant 85 mg twice daily or placebo for one week prior to a 1 mg injection of Wegovy. Patients then received either tradipitant or placebo for another week while also receiving Wegovy.
For the primary endpoint, while 58.6% of those in the placebo group reported vomiting, only 29.3% in the tradipitant group did. In the placebo cohort, 48.3% reported vomiting and nausea, compared to 22.4% for those on tradipitant. This was a secondary endpoint.
Vanda said a phase 3 trial is planned to begin in H1 2026.
The company acquired the oral neurokinin-1 (NK-1) receptor antagonist from Eli Lilly (LLY) in 2012.
Separately, the US Supreme Court on Monday rejected Vanda's request to review a US FDA decision that denied Fast Track status for

More on Vanda Pharmaceuticals